1. Revascularisation of complex patients in stable coronary artery disease

A predictor for 10-year mortality and clinical events in patients with chronic coronary total occlusion lesion

K Kim

  • 10 years of clinical follow-up, MACCE occurs 6%, all-cause death in 18.5%, cardiac death in 9.9%, myocardial infarction (MI) 7.7%, revascularization in 30.7%, and stroke in 6.3% of patients
  • A prior myocardial infarction, reduced LV ejection fraction, chronic kidney disease, and multi-vessel disease were associated with an increased risk of MACCE
  • While the use of statins and aspirin reduced the risk of MACCE
  • PCI for CTO lesions did not reduce the incidence of MACCE or all-cause death


  1. Partnering with patients through digital health

Quality of life after pulmonary veins isolation: outcomes from a digital follow-up program

R Teixeira

  • No significant differences were seen according to baseline age and AF type
  • During follow-up, AF recurred in 14.5% of patients, < 7% of patients had at least one emergency department visit and no deaths were reported
  • Among patients with symptomatic AF, ablation led to significant improvements in QoL at 12 months
  • Males in whom antiarrhythmic drugs were discontinued reported higher improvement in QoL


  1. Hypertension phenotypes and arterial stiffness

Arterial stiffness assessment in patients with resistant hypertension using pulse wave analysis

       A Akhmimi

  • The office and central BP readings were elevated in the resistant hypertension (RH) group compared to essential hypertension (CH) and normotensive (NC) (P<0.001)
  • Aortic pulse pressure, MAP, and aortic augmentation pressure were significantly increased in patients with RH compared to other groups (P<0.001)
  • Elevated AIx (Aortic augmentation index) was significantly and independently associated with the presence of RH


  1. Diabetes and stable coronary artery disease

Real-life use of novel glucose-lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes – experience from national use in the SWEDEHEART registry

V Ritsinger 

  • The use of novel glucose-lowering agents increased rapidly from 7% to 47% from 2016 year
  • Use of SGLT2i increased from 4% to 38% and GLP-1 RA from 4% to 15%
  • The cumulative event rate in all-cause death within 1 year occurred in 7% of patients with SGLT2i and/or GLP-1 RA compared to 4.5% in patients without new cardioprotective agents
  • Increased awareness is needed to use effective cardioprotective treatment also in a high-risk population


  1. Effect of initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy on ambulatory blood pressure indices

J Nolde

  • At 12 weeks, mean 24-h ambulatory systolic and diastolic BP were 7 and 5.3 mmHg lower in the quadpill versus monotherapy group (p<0.001 for both)
  • The reduction in systolic and diastolic ambulatory BP variability was more pronounced in the quadpill group at 12 weeks
  • The rate of BP control at 12 weeks was higher in the quadpill group (p<0.001). These effects were maintained at 52 weeks.
  • A quadruple quarter-dose combination compared to monotherapy resulted in greater ambulatory BP lowering across the entire 24-hour period with higher ambulatory BP control rates at both 12 and 52 weeks


  1. Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: A systematic review and meta-analysis

DA Gorog

  • Reduced DAPT intensity attenuated major bleeding (p=0.009) without impacting net adverse cardiovascular events (NACE) or major adverse cardiovascular events (MACE)
  • In East Asians (EA), it reduced major bleeding (p=0.02) without affecting NACE or MACE
  • Individualisation of DAPT strategy may be preferable to personalise care based on both ethnicity and prevailing risks
  • Standard DAPT favours patients at high ischaemic risk, while shorter or less intense DAPT may benefit those at high bleeding risk


  1. MINOCA in a young patient with antiphospholipid syndrome

M Bernardo

  • Antiphospholipid syndrome can cause venous or arterial thrombosis and should be considered in young patients presenting with a myocardial infarction, as it might be the initial sign of the syndrome.
  • In the presenting case of MINOCA, CMR was essential for diagnosis
  • An ICD is recommended in patients with symptomatic HF and LVEF ≤35% despite ≥3 months of OMT


  1. Short and optimal duration of dual-antiplatelet therapy study after everolimus-eluting cobalt-chromium stent-3

STOPDAPT-3: An Aspirin-Free antithrombotic strategy for percutaneous coronary intervention

Natsuaki M

  • Aspirin-free strategy using low-dose Prasugrel compared with DAPT failed to attest superiority for major bleeding within 1 month after PCI
  • Aspirin used for limited period after PCI, DAPT exerted protective effect on coronary lesions regardless of the treatment
  • No-aspirin group compared to DAPT was associated with excess of coronary events


  1. Functional versus Culprit-only revascularization in elderly patients with myocardial infarction and multivessel disease

 FIRE trial: Physiology-Guided Complete PCI in Older MI Patients

S Biscaglia

  • Among patients aged ≥75 years with MI complete revascularization as compared to culprit-only revascularization strategy, reduced
  • composite of death, MI, stroke, or ID revascularization
  • Cardiovascular death or MI
  • The safety endpoint in culprit-only reported 20.4% and for complete 22.5%


  1. MI Trajectory- Subsequent cardiovascular disease trajectories following myocardial infarction

    C Nathalie

  • The study reported that cardiovascular diseases showed 47% mortality compared to lung diseases(20%) and infections (8%)
  • Heart failure is the strongest predictor of mortality (more than MI)
  • Important reductions in in-hospital mortality among patients with MI have translated in modest improvements in long-term survival
  • Heart failure is the common consequence of MI
  • Heart failure should be the focus for new preventive strategies after MI